Neogen Corporation (NEOG) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Neogen Corporation $5.09, price $13.57, upside -62.5%, quality 17 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Neogen Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $4.39 – $46.65 · fair‑value band $2.92 – $7.26 · the $13.57 price screens above the $5.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Neogen in your weekly email
Every Wednesday you see whether Neogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety.
Show more
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Stock analysis
Neogen Corporation (NEOG) currently trades at $13.57, while our model-based Fair Value estimate is $5.09, implying the stock looks roughly 166.6% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 5 models at a data quality of 95/100, which puts the evidence level at medium.
Scenario range: $2.92 (bear) to $7.26 (bull), the price of $13.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Neogen Corporation reported revenue of $895M in FY2025 versus $468M in FY2021, a compound +17.6%/yr. Reported net income was −$1.1B in FY2025.
Key figures
Market cap $2.9B · P/S ratio 2.58 · EPS (TTM) $−2.90 · Net margin −122% · Return on equity −25.6% · Return on assets (EBIT) 3.4% · Operating margin −1.6% · Revenue (TTM) $871M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 153% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −62%, NEOG screens richer than that median.
Fair Value models
Bear $2.92Fair Value $5.09Bull $7.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Start year 2020 (pandemic). Over 10 years: +12.2% a year
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.4% (2019) → 8.4% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score17 · Bottom 25%
Fair Value upside−63% · Bottom 25%
Profitability
Return on assets−1% · Below median
Net margin (TTM)−70% · Bottom 25%
Operating margin (TTM)−2% · Below median
Growth and dividend
Revenue growth−4% · Below median
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.42× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)3.38× · Pricier than median
EV/EBITDA45.4× · Priciest 25%
PEG0.66× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 11
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)79· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Neogen Corporation Fair Value". https://www.fairvalue-calculator.com/stock/NEOG
Frequently asked questions
Is Neogen Corporation (NEOG) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $5.09 versus a price of $13.57, about −62% upside (overvalued).
What is the fair value of NEOG?
Our model-based fair value for Neogen Corporation is $5.09 (as of Sep 24, 2026), built from audited fundamentals. The current price: $13.57.
What is the quality score of NEOG?
Neogen Corporation has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neogen Corporation (NEOG)?
Our model-based price target is the fair value of $5.09 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario $2.92, optimistic scenario $7.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Neogen Corporation stock forecast for 2026?
Our models put fair value at $5.09, about −62% upside versus a price of $13.57 (overvalued). Cautious scenario $2.92, optimistic scenario $7.26. The calculation is refreshed regularly with new filings.
What is the revenue of Neogen Corporation (NEOG)?
Neogen Corporation reported trailing-twelve-month revenue of about $871M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Neogen Corporation (NEOG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neogen Corporation it is $5.09 per share (as of Sep 24, 2026), against a price of $13.57. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Neogen Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NEOG trades above its calculated fair value: price $13.57, fair value $5.09, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEOG?
No. The price is what the market pays today ($13.57); the fair value is what the company's own numbers justify ($5.09). For Neogen Corporation the two are $8.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neogen Corporation worth?
The market values Neogen Corporation at about $2.9B (market capitalisation, as of Sep 24, 2026). Per share that is $13.57; our models calculate a fair value of $5.09 per share.
What do the bullish and bearish scenarios say about NEOG?
Our models span a range for Neogen Corporation: cautious scenario $2.92, base $5.09, optimistic $7.26 per share (as of Sep 24, 2026, price $13.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of NEOG?
The PEG ratio of Neogen Corporation is 0.66 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Neogen Corporation (NEOG)?
Balance-sheet figures for Neogen Corporation (as of Sep 24, 2026): return on equity −25.6%, debt of 0.42 per unit of equity. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is NEOG from its 52-week high?
Neogen Corporation trades at $13.57, about 3% below its 52-week high of $13.98 and 153% above the low of $5.36 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.09 is for.
Which stocks are comparable to Neogen Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neogen Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $13.57, calculated fair value $5.09 (−62%), Quality Score 17/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEOG calculated?
We run Neogen Corporation through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Neogen Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neogen Corporation (NEOG)?
The closing price on Sep 23, 2026 was $13.57. Our model-based fair value is $5.09, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neogen Corporation right now?
The price sits above even our optimistic bull case ($7.26). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($2.92 to $7.26) leaves room in how you read the outcome.
Key figures of Neogen Corporation
How large is the market capitalisation of Neogen Corporation (NEOG)?
The market capitalisation of Neogen Corporation is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neogen Corporation (NEOG)?
The price-to-sales ratio of Neogen Corporation is 2.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neogen Corporation (NEOG)?
Earnings per share at Neogen Corporation are $−2.90. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neogen Corporation (NEOG)?
The net margin of Neogen Corporation is −122% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neogen Corporation (NEOG)?
The return on equity (ROE) of Neogen Corporation is −25.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neogen Corporation (NEOG)?
On an EBIT basis the return on assets of Neogen Corporation is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neogen Corporation (NEOG)?
The operating margin of Neogen Corporation is −1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neogen Corporation (NEOG)?
Revenue at Neogen Corporation is growing −4.4% versus a year earlier (3y avg +19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neogen Corporation (NEOG)?
Earnings per share at Neogen Corporation are growing −85.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Neogen Corporation (NEOG) generate?
The free cash flow of Neogen Corporation is −$46.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Neogen Corporation (NEOG) carry?
The net debt of Neogen Corporation is $784M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Neogen Corporation in the live analysis
One click puts Neogen Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026